Study on TFF1 and PALB2 gene variants associated with gastric carcinoma risk in the Chinese Han population |
| |
| Institution: | 1. Department of Digestive Internal Medicine, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China;2. Department of Digestive Internal Medicine, Xi’an Fifth Hospital, Xi’an 710082, China;3. Department of First Internal Medicine, Shaanxi Province Cancer Hospital, Xi’an 710061, China;4. Department of Pathology, Xi’an Jiaotong University Health Science Center, Xi’an 710061, China;5. Department of Sixth Internal Medicine, Shaanxi Province Cancer Hospital, Xi’an 710061, China;1. Department of Hematology, Institut d’hématologie de Basse-Normandie, University Hospital, Normandy University, School of Medicine, Caen, France;2. Department of Research, University Hospital, Caen, France;3. ANTICIPE U1086 Inserm-University of Caen, Centre François Baclesse, Caen, France;4. Laboratory of Hematology, University Hospital, Caen, France;5. Registre Régional des Hémopathies malignes de Basse-Normandie, University Hospital of Caen, Caen, France;1. Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Damascus University, Damascus, Syria;2. Faculty of Medicine, Albaath University, Homs, Syria;3. Faculty of Medicine, Damascus University, Damascus, Syria;4. Department of Oncology, Faculty of Medicine, Damascus University, Damascus, Syria;1. Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL, Hospitalet de Llobregat, 08908 Barcelona, Spain;2. Biomedical Research Centre Network for Oncology (CIBERONC), Instituto Salud Carlos III, 28029 Madrid, Spain;3. Hereditary Cancer Program, Catalan Institute of Oncology, Badalona 08916, Barcelona, Spain;4. Department of Pathology, Bellvitge University Hospital, Hospitalet de Llobregat, 08907 Barcelona, Spain;5. Department of Gastroenterology, Bellvitge University Hospital, Hospitalet de Llobregat, 08907 Barcelona, Spain;6. Department of General Surgery, Bellvitge University Hospital, Hospitalet de Llobregat, 08907 Barcelona, Spain;7. Colorectal Cancer Multidisciplinary Board, Catalan Institute of Oncology, Hospitalet de Llobregat, 08908 Barcelona, Spain;8. Colorectal Cancer Multidisciplinary Board, Bellvitge University Hospital, Hospitalet de Llobregat, 08907 Barcelona, Spain;9. Department of Medical Oncology, Catalan Institute of Oncology, Hospitalet de Llobregat, 08908 Barcelona, Spain;10. Bellvitge Health Sciences Campus, University of Barcelona, Hospitalet de Llobregat, 08908 Barcelona, Spain;11. Department of Radiation Oncology, Catalan Institute of Oncology, Hospitalet de Llobregat, 08908 Barcelona, Spain;12. Hereditary Cancer Program, Catalan Institute of Oncology-IDIBGI, OncoGir-Pro, 17007 Girona, Spain;1. Department of Gastroenterology, Mater Misericordiae University Hospital, Dublin, Ireland;2. School of Medicine, University College Dublin, Ireland;3. Centre for Colorectal Disease, St Vincent’s University Hospital, Dublin, Ireland;4. Department of Pathology, Mater Misericordiae University Hospital, Dublin, Ireland;5. Department of Pathology, St Vincent’s University Hospital, Dublin, Ireland;6. Department of Colorectal Surgery, St Vincent’s University Hospital, Dublin, Ireland;1. The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia;2. Sydney School of Public Health, The University of Sydney, Australia;3. School of Public Health and Social Work, Queensland University of Technology, Brisbane, Australia;4. Australian Centre for Health Services Innovation & Centre for Healthcare Transformation, Queensland University of Technology, Brisbane, Australia;5. Faculty of Medicine and Health, Sydney Health Literacy Lab, School of Public Health, The University of Sydney, Sydney, Australia;6. School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia;7. Cancer Council Queensland, Brisbane, Australia;8. Centre for Data Science, Queensland University of Technology, Brisbane, Australia;9. Menzies Health Institute, Griffith University, Gold Coast, Australia |
| |
| Abstract: | ObjectiveGastric carcinoma (GC) has received extensive attention due to its complex pathogenesis. Studies have shown that the expression of Trefoil factor 1 (TFF1) and Partner and localiser of BRCA2 (PALB2) genes promotes the occurrence of GC. Therefore, we investigated whether TFF1 and PALB2 gene polymorphisms are associated with GC risk in the Chinese Han population.MethodsA total of 509 GC cases and 505 controls were recruited, and single nucleotide polymorphisms (SNPs) of TFF1 and PALB2 in these subjects were genotyped. The association between each candidate polymorphism and GC risk was assessed by calculating odds ratios (ORs) and 95% confidence intervals (CIs). The visualization of gene-gene interactions and functional enrichment analysis were then performed using Cytoscape software and the R package “cluster profile”.ResultsThe TFF1 rs2156310 polymorphism significantly reduced the predisposition to GC in people under 60 years of age (AA vs. AG - GG, OR = 0.58, 95% CI = 0.35–0.97, p = 0.036). The gender-stratified analysis found that PALB2 rs513313 was significantly associated with the risk of GC in males (CT vs. TT, OR = 1.51, 95% CI = 1.06–2.15, p = 0.022). Besides, PALB2 rs249954 significantly reduced the susceptibility to GC in females (AA vs GG, OR = 0.42, 95% CI = 0.19–0.94, p = 0.034).ConclusionOur results revealed that TFF1 and PALB2 gene polymorphisms were correlated with the genetic susceptibility to GC, providing certain data support for researchers to further study the mechanism of GC. |
| |
| Keywords: | Gastric carcinoma Gene polymorphisms Chinese Han population |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
